How Is the Best Prostate Cancer Treatment Determined?

After being diagnosed with prostate cancer, many patients feel a sense of urgency to begin treatment straight away. However, one patient may be advised to undergo immediate surgery or radiotherapy, while another person may only receive monitoring without immediate treatment. It can be difficult to understand why the recommended approach can vary so much when it comes to this condition.

This is because a prostate cancer diagnosis does not, by itself, reveal how likely the cancer is to develop or the level of risk it poses. Your doctor needs to consider the characteristics of the tumour and the extent of the cancer, alongside your overall health and individual circumstances before making a decision. Together, these findings help determine whether treatment is needed and which approach may be most appropriate.

What Determines Whether Prostate Cancer Needs Treatment?

Determining the appropriate approach to prostate cancer treatment first requires the doctor to establish how extensive the cancer is and how aggressively it is likely to behave. During diagnosis and further assessment, the doctor gathers information about the cancer through findings such as imaging, prostate biopsy results and prostate-specific antigen (PSA) levels. Together, these help establish how extensive the cancer is and how aggressively it is likely to behave.

Clinical stage, Grade Group and PSA therefore provide different pieces of the overall picture. Considering them together helps the doctor assess the risk posed by the cancer and provides the clinical foundation for later decisions about whether monitoring or treatment is appropriate.

How Far Has Cancer Developed?

Clinical stage describes how far the cancer has developed anatomically. The tumour-node-metastasis (TNM) system considers the extent of the tumour in and around the prostate, whether regional lymph nodes are involved and whether cancer has spread to distant parts of the body.

A tumour confined to the prostate therefore presents a different treatment problem from cancer that has already extended beyond it. The stages of prostate cancer bring these findings together to describe how advanced the disease is.

The purpose of staging is not simply to assign a stage number. It establishes the extent of disease that a management plan may eventually need to address, giving the doctor a clearer starting point for judging the significance of the diagnosis.

How Aggressive Is Cancer Likely To Be?

Knowing where the cancer is does not fully explain how it is likely to behave. When prostate tissue collected during a biopsy is examined under a microscope, the appearance of the cancer cells is used to determine the Grade Group. This provides information about how aggressively the cancer may grow and spread.

The PSA level adds further context when considered alongside the Grade Group and clinical stage. Looking at these findings together helps distinguish between cancers that may be similar in extent but carry different risks of progression.

This distinction is important because a cancer being localised does not automatically mean it is low risk. Likewise, the presence or absence of early warning signs of prostate cancer does not provide the same information about how advanced or aggressive an established cancer is.

When May Earlier-Stage Prostate Cancer Continue to Be Monitored?

For some men with earlier-stage, lower-risk disease, treatment may not need to begin immediately. Active surveillance can instead keep the cancer under close review while preserving the option to intervene if later findings show that its behaviour has changed.

If the Benefits of Immediate Treatment Are Limited

When the expected risk of progression is relatively low, treating the cancer straight away may provide limited additional benefit at that point compared with monitoring it closely.

This matters because treatments such as surgery and radiotherapy can affect urinary, sexual or bowel function. If immediate treatment is unlikely to improve cancer control enough to justify those effects yet, surveillance can allow them to be deferred while the cancer remains closely monitored.

Active surveillance is therefore not simply a decision to leave the cancer alone. It is a way of avoiding treatment before its expected benefit becomes great enough to outweigh its potential effects.

If the Cancer Continues to Show Lower-Risk Features

The decision to monitor is not permanent. Follow-up is designed to check whether the assumptions that made surveillance appropriate still hold over time.

Prostate-specific antigen levels can be followed for changes or trends that warrant closer assessment. Magnetic resonance imaging (MRI) or a repeat biopsy may then provide more direct information about whether the cancer has changed.

A rising PSA does not necessarily mean that treatment must begin immediately. Instead, it can prompt further assessment to determine whether there is stronger evidence of progression. If subsequent findings show that the cancer no longer fits a lower-risk pattern, the management plan can then be reconsidered using the updated information.

When Is Active Treatment More Likely to Be Recommended?

When the expected benefit of controlling the cancer becomes greater than the benefit of continuing to defer treatment, management shifts towards active intervention. The question then becomes what level of treatment is needed for the extent of disease already established.

If Higher-Risk Cancer Is Still Confined to the Prostate

Cancer does not have to spread outside the prostate before active treatment becomes appropriate. If the overall assessment indicates clinically significant localised disease, allowing it to progress untreated may carry greater risk than intervening while treatment can still be directed at the prostate.

For suitable patients, surgery or radiotherapy may therefore be considered with curative intent. At this stage, the decision is no longer primarily about whether surveillance is reasonable, but which appropriate treatment offers a suitable balance of cancer control and treatment effects.

Overall health, expected treatment benefit and existing urinary or sexual function can help distinguish between suitable approaches when more than one option is available.

If Cancer Has Extended Beyond the Prostate

When cancer extends beyond the prostate, simply treating the prostate itself may no longer address the full extent of the disease. The management plan has to account for where cancer is present and how broadly treatment needs to work.

For locally advanced disease, treatment may involve radiotherapy combined with hormone therapy, while surgery can remain an option in selected patients as part of a broader treatment plan. If cancer has spread to distant sites, treatments that act throughout the body become more important because disease is no longer confined to one area.

At this point, stage also changes the purpose and scope of treatment, from controlling disease within the prostate to managing cancer that may be present beyond it.

Discuss Your Prostate Cancer Treatment With Dr Michael Wong

A prostate cancer diagnosis is only the beginning of the treatment decision. Before deciding how to proceed, your cancer needs to be considered in terms of its stage, aggressiveness and risk of progression, alongside your overall health and the potential benefits and effects of treatment.

This is where a specialist assessment can help bring the different findings together. At the International Urology, Fertility and Gynaecology Centre , Senior Consultant Urologist Dr Michael Wong assesses each patient's prostate cancer and discusses whether continued monitoring or active treatment may be appropriate. His approach considers both the characteristics of the cancer and the individual patient's circumstances when weighing the available management options.

If you have received a prostate cancer diagnosis or are considering your treatment options, book an appointment with Dr Wong to discuss your findings and what they may mean for your next steps.

FAQs